Clinical Trial Update: ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Alicaforsen (ISIS 2302) in mild to moderate active ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Alicaforsen (alicaforsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED